Weight Loss Peptides: Semaglutide, Tirzepatide, Retatrutide These peptides have the strongest human safety data of any class because they have been through large-scale, FDA-regulated clinical trials
The pharmacokinetic and toxicity properties of the lead compounds (CB-27, CB-41, CB-50, CB-53, CB-58, CB-59, and CB-61) were compared to CQ (Supplementary Table S6)
To view or add a comment, sign in Genentech Reports the US FDA's Approval of Gazyva (Obinutuzumab) to Treat Lupus Nephritis #genentech #gazyva #obinutuzumab #lupusnephritis #usfda #regulatory #monoclonalantibody #nobility #regency #pii #piii #ro5072759 #rg7159 #r7159 #ga101 To view or add a comment, sign in Potential future royalty income from Metsera/Pfizer* obesity drug candidates As highlighted in our 2025 half-yearly results, IP Group has financial exposure to several of Metseras obesity drug programmes, following its acquisition of our former portfolio company Zihipp Limited in 2023
It is administered via subcutaneous injection, though oral formulations are also being studied